Geron (GERN) Retained Earnings (2010 - 2026)
Geron's (GERN) quarterly Retained Earnings came in at -$1.9 billion in Q2 2026, down 3.74% year-over-year from -$1.9 billion in Q2 2025, and down 0.9% quarter-over-quarter from -$1.9 billion in Q1 2026.
Analysis
Geron (GERN) Retained Earnings (2010 - 2026) Analysis & Trends
Geron has disclosed Retained Earnings across 17 years of filings, most recently posting -$1.9 billion for Q2 2026.
- In Q2 2026, Retained Earnings fell 3.74% year-over-year to -$1.9 billion; the TTM figure through Jun 2026 stood at -$1.9 billion (down 3.74% YoY), while the FY2025 annual figure was -$1.9 billion, down 4.71% from the prior year.
- Retained Earnings came in at -$1.9 billion for Q2 2026 at Geron, down from -$1.9 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$1.3 billion in Q1 2022 to a low of -$1.9 billion in Q2 2026.
- Average Retained Earnings over 5 years is -$1.6 billion, with a median of -$1.7 billion recorded in 2024.
- Year-over-year, Retained Earnings declined 14.63% in 2024 and declined 3.74% in 2026.
- Over 5 years, Retained Earnings stood at -$1.4 billion in 2022, then declined by 13.03% to -$1.6 billion in 2023, then decreased by 10.93% to -$1.8 billion in 2024, then declined by 4.71% to -$1.9 billion in 2025, then slipped by 1.1% to -$1.9 billion in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$1.9 billion in Q2 2026, -$1.9 billion in Q1 2026, and -$1.9 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | -1.88 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.88 Bn |
| Mar 31, 2026 | -1.86 Bn |
| Dec 31, 2025 | -1.86 Bn |
| Sep 30, 2025 | -1.83 Bn |
| Jun 30, 2025 | -1.81 Bn |
| Mar 31, 2025 | -1.79 Bn |
| Dec 31, 2024 | -1.77 Bn |
| Sep 30, 2024 | -1.75 Bn |
| Jun 30, 2024 | -1.72 Bn |
| Mar 31, 2024 | -1.65 Bn |
| Dec 31, 2023 | -1.60 Bn |
| Sep 30, 2023 | -1.55 Bn |
| Jun 30, 2023 | -1.50 Bn |
| Mar 31, 2023 | -1.45 Bn |
| Dec 31, 2022 | -1.41 Bn |
| Sep 30, 2022 | -1.37 Bn |
| Jun 30, 2022 | -1.33 Bn |
| Mar 31, 2022 | -1.30 Bn |
| Dec 31, 2021 | -1.27 Bn |
| Sep 30, 2021 | -1.24 Bn |